Document Detail

Serum total gangliosides and TA90-IC levels: novel immunologic markers in colorectal cancer.
MedLine Citation:
PMID:  11898807     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Because of the challenge in defining prognostic markers predictive of recurrence or progression, carcinoembryonic antigen (CEA) remains the most frequently used marker in colorectal cancer, despite its low sensitivity. We hypothesized that TA90-IC status and serum ganglioside levels might be useful markers and might be of prognostic significance in colorectal cancer. METHODS: Serum samples from 68 patients undergoing surgical treatment for histologically proven colorectal cancer were analyzed for the presence of CEA, serum gangliosides, and TA90-IC. Forty-one patients had node-negative disease, whereas 27 patients had limited metastatic disease. The intent was curative resection, even for patients with metastatic disease. Cryopreserved serum specimens were analyzed in a blinded fashion for total serum ganglioside levels (by an assay that detects lipid-associated sialic acids), for CEA, and for TA90-IC (by a murine monoclonal antibody-based enzyme-linked immunosorbent assay). A positive value for TA90-IC levels was defined as an optical density (OD) of more than 0.410 at 405 nm. RESULTS: Serum ganglioside levels were elevated more frequently than CEA concentrations (84% vs 44%). The combination of serum ganglioside and CEA values was more sensitive (88%) than CEA value alone (44%) in identifying patients with early-stage colorectal cancer. TA90-IC levels were elevated more frequently than CEA concentrations (56% vs 32%). The combination of TA90-IC and CEA values was more sensitive (72%) than CEA value alone (32%) in identifying patients with advanced-stage colorectal cancer. At an enzyme-linked immunosorbent assay cutoff level of 0.410, 15 (56%) patients had positive TA90-IC values. Fourteen patients alive with residual disease had a median OD TA90-IC level of 0.879, and only three patients had levels below the OD cutoff value of 0.410. Thirteen patients with no evidence of disease had a median level of 0.277, and only four patients had OD levels > or = 0.410. TA90-IC was significantly higher in the alive with residual disease patients than those rendered no evidence of disease (P = 0.02). CONCLUSIONS: We speculate that a multiple-marker analysis that combines CEA values with serum ganglioside and TA90-IC values may be more sensitive than CEA value alone for detecting colorectal cancer. The potential prognostic significance of TA90-IC status in advanced disease warrants further investigation.
Carlos A Perez; Mepur H Ravindranath; Rishab K Gupta; Rob A E M Tollenaar; Cornelius J van de Velde; Thomas F Wood; Daniel Soh; Donald L Morton; Anton J Bilchik
Related Documents :
7261317 - Case report: changes in creatine kinase isoenzymes after myocardial infarction in a pat...
18217197 - Efficacy of high-dose intravenous immunoglobulin therapy in japanese patients with ster...
18436407 - Evaluation of the role of magnetization transfer imaging in prostate: a preliminary study.
10407867 - Serum ca 125 levels in children with non-hodgkin's lymphoma.
20421807 - Variation in barrett's esophageal wall thickness: is it associated with histology or se...
8659237 - Coronary artery bypass surgery on the beating heart.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cancer journal (Sudbury, Mass.)     Volume:  8     ISSN:  1528-9117     ISO Abbreviation:  Cancer J     Publication Date:    2002 Jan-Feb
Date Detail:
Created Date:  2002-03-15     Completed Date:  2002-10-22     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  100931981     Medline TA:  Cancer J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  55-61     Citation Subset:  IM    
Laboratory of Glyco-Immunotherapy, John Wayne Cancer Institute, Santa Monica, California 90404-23023, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibodies, Monoclonal
Antigens, Neoplasm / blood*
Carcinoembryonic Antigen / blood*
Colonic Neoplasms / blood*,  immunology
Enzyme-Linked Immunosorbent Assay
Gangliosides / blood*
Middle Aged
Rectal Neoplasms / blood*,  immunology
Sensitivity and Specificity
Tumor Markers, Biological / blood*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antigens, Neoplasm; 0/Carcinoembryonic Antigen; 0/Gangliosides; 0/TA90 immune complex; 0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Image-guided radiofrequency ablation of spinal tumors: preliminary experience with an expandable arr...
Next Document:  A personal encounter with psychology (1937-2002).